Autolus Therapeutics plc Selling, General and Administrative Expense
Autolus Therapeutics plc (AUTL) reported Selling, General and Administrative Expense of $41.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- Autolus Therapeutics plc selling, general and administrative expense for the quarter ending 2026-06-30 was $41.16M, a 36.00% increase year-over-year.
- Autolus Therapeutics plc selling, general and administrative expense for the quarter ending 2026-03-31 was $39.95M, a 35.26% increase year-over-year.
- Autolus Therapeutics plc selling, general and administrative expense for the quarter ending 2025-12-31 was $35.80M, a 4.32% increase year-over-year.
- Autolus Therapeutics plc selling, general and administrative expense for the quarter ending 2025-09-30 was $36.28M, a 32.75% increase year-over-year.
- Autolus Therapeutics plc selling, general and administrative expense for fiscal 2025 was $131.87M, a 29.64% increase from fiscal 2024.
- Autolus Therapeutics plc selling, general and administrative expense for fiscal 2024 was $101.72M, a 117.61% increase from fiscal 2023.
- Autolus Therapeutics plc selling, general and administrative expense for fiscal 2023 was $46.74M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $41.16M 10-Q · filed 2026-08-11 | $81.11M 10-Q · filed 2026-08-11 | $116.91M derived: sum of 3 quarters · filed 2026-08-11 | $153.19M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $39.95M 10-Q · filed 2026-05-14 | $75.75M derived: sum of 2 quarters · filed 2026-05-14 | $112.03M derived: sum of 3 quarters · filed 2026-05-14 | $142.29M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $35.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $72.08M derived: sum of 2 quarters · filed 2026-03-27 | $102.34M derived: sum of 3 quarters · filed 2026-08-11 | $131.87M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $36.28M 10-Q · filed 2025-11-12 | $66.55M derived: sum of 2 quarters · filed 2026-08-11 | $96.08M 10-Q · filed 2025-11-12 | $130.40M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $30.27M 10-Q · filed 2026-08-11 | $59.80M 10-Q · filed 2026-08-11 | $59.80M 10-Q · filed 2025-08-12 | $94.11M derived: sum of 3 quarters · filed 2026-08-11 | $121.44M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $29.54M 10-Q · filed 2026-05-14 | $29.53M 10-Q · filed 2025-05-08 | $63.85M derived: sum of 2 quarters · filed 2026-05-14 | $91.18M derived: sum of 3 quarters · filed 2026-05-14 | $113.08M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $34.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $61.64M derived: sum of 2 quarters · filed 2026-03-27 | $83.55M derived: sum of 3 quarters · filed 2026-03-27 | $101.72M 10-K · filed 2026-03-27 | $101.09M 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $27.33M 10-Q · filed 2025-11-12 | $49.23M derived: sum of 2 quarters · filed 2025-11-12 | $67.41M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | $21.90M 10-Q · filed 2025-08-12 | $40.08M 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | $18.18M 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | $46.74M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |